Cytokinetics Q1 2024 GAAP EPS $(1.33) Misses $(1.18) Estimate, Sales $835.000K Miss $899.615K Estimate
Portfolio Pulse from Benzinga Newsdesk
Cytokinetics reported Q1 2024 GAAP EPS of $(1.33), missing the $(1.18) estimate, with sales of $835K also missing the $899.615K estimate. This represents an 81.90% decrease in sales compared to the same period last year.
May 08, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cytokinetics missed Q1 2024 earnings and sales estimates, with a significant year-over-year decrease in sales.
Missing both earnings and sales estimates, especially with a substantial year-over-year sales decrease, is likely to negatively impact investor sentiment and the stock price in the short term. The magnitude of the miss and the significant decrease in sales compared to the previous year highlight operational challenges that could concern investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100